This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wolf, K.
Right arrow Articles by Malinverni, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wolf, K.
Right arrow Articles by Malinverni, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 1999, p. 1491-1493, Vol. 43, No. 6
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Effect of Azithromycin plus Rifampin versus That of Azithromycin Alone on the Eradication of Chlamydia pneumoniae from Lung Tissue in Experimental Pneumonitis

Katerina Wolf1 and Raffaele Malinverni1,2,*

Department of Clinical Research1 and Medical Policlinic,2 Inselspital, University of Bern, Bern, Switzerland

Received 3 June 1998/Returned for modification 3 November 1998/Accepted 11 March 1999

Azithromycin, doxycycline, and rifampin, alone or in combination, were tested in vitro against Chlamydia pneumoniae AR-39. The combination of azithromycin plus rifampin showed the strongest activity and produced higher rates of eradication of C. pneumoniae from lung tissues than azithromycin alone in experimental mouse pneumonitis.

* Corresponding author. Mailing address: Medical Policlinic, Inselspital, 3010 Bern, Switzerland. Phone: 031 632 27 45. Fax: 031 632 31 76. E-mail: raffaele.malinverni{at}insel.ch.

Antimicrobial Agents and Chemotherapy, June 1999, p. 1491-1493, Vol. 43, No. 6
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Rios, A. M., Fonseca-Aten, M., Mejias, A., Chavez-Bueno, S., Katz, K., Gomez, A. M., McCracken, G. H. Jr., Ramilo, O., Hardy, R. D. (2005). Microbiologic and Immunologic Evaluation of a Single High Dose of Azithromycin for Treatment of Experimental Mycoplasma pneumoniae Pneumonia. Antimicrob. Agents Chemother. 49: 3970-3973 [Abstract] [Full Text]  
  • Siewert, K., Rupp, J., Klinger, M., Solbach, W., Gieffers, J. (2005). Growth Cycle-Dependent Pharmacodynamics of Antichlamydial Drugs. Antimicrob. Agents Chemother. 49: 1852-1856 [Abstract] [Full Text]  
  • de Kruif, M. D., van Gorp, E. C.M., Keller, T. T., Ossewaarde, J. M., ten Cate, H. (2005). Chlamydia pneumoniae infections in mouse models: relevance for atherosclerosis research. Cardiovasc Res 65: 317-327 [Abstract] [Full Text]  
  • Stone, A. F.M., Mendall, M. A., Kaski, J.-C., Edger, T. M., Risley, P., Poloniecki, J., Camm, A. J., Northfield, T. C. (2002). Effect of Treatment for Chlamydia pneumoniae and Helicobacter pylori on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 106: 1219-1223 [Abstract] [Full Text]  
  • Bin, X. X., Wolf, K., Schaffner, T., Malinverni, R. (2000). Effect of Azithromycin plus Rifampin versus Amoxicillin Alone on Eradication and Inflammation in the Chronic Course of Chlamydia pneumoniae Pneumonitis in Mice. Antimicrob. Agents Chemother. 44: 1761-1764 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»